Kaitlyn D’Onofrio

DocwireNews

A recent study explored the effect of <a href="https://www.docwirenews.com/abstracts/hem-onc-abstracts/hypofractionated-radiation-therapy-for-unresectable-locally-recurrent-intrahepatic-cholangiocarcinoma/">robotic stereotactic body radiotherapy (SBRT)</a> in patients with oligorecurrent <a href="https://www.docwirenews.com/abstracts/hem-onc-abstracts/wedge-resection-of-tumor-before-lobectomy-for-lung-cancer-could-be-a-no-touch-isolation-technique/">lung metastases</a> (ORLM).&ldquo;Resection of lung metastases (metastasectomy) has become a widespread and accepted standard therapy. However, evidence for pulmonary metastasectomy is weak as no randomized clinical trials exist to support its benefit. In case of oligometastatic lung disease (OMLD), less invasive interventions such as radiofrequency- and microwave ablation and stereotactic body radiotherapy (SBRT) have been described as a valid alternative to surgery,&rdquo; the study authors explained.&ldquo;The major challenge when delivering SBRT to lung metastases is to manage respiratory motion of both tumor and normal tissues. Breathing control strategies such as breath-hold, gating, tumor tracking and motion management techniques have been implemented to deal with this challenge. One of those strategies is the Cyberknife&reg; synchrony (Accuray Inc., Sunnyvale, CA), which performs real-time tumor tracking. This allows for a high level of precision while treating the patient in the comfort of free breathing.&rdquo;To conduct their study, patients with up to five ORLM underwent SBRT with the Cyberknife&reg;. The intended dose was 60Gy in 3 fractions, which was prescribed to the 80% isodose volume. Tumor control and toxicity were evaluated. Outcomes included the effect of tumor-, patient-, and treatment-related parameters on local control (LC), and lung and distant progression free- (lung PFS/Di-PFS) and overall survival (OS).A total of 104 ORLM patients (132 lesions) between May 2010 and March 2016 were retrospectively reviewed. Lesions were irradiated from primary lung carcinoma (47%) as well as gastro-intestinal (GI) (34%) and mixed primary histologies (19%); tumors had a mean 7.9 cc volume. Median follow-up time was 22 months. The one-year LC rate (per lesion) was 89.3%, the two-year rate were 80.0%, and the three-year rate was 77.8%, respectively; at the same time points, the per patient lung PFS were 66.3%, 50.0%, and 42.6%, respectively; DiPFS, 80.5%, 64.4%, and 60.6%, respectively; and OS, 92.2%, 80.9%, and 72.0%, respectively. univariable analysis found that when GI was the primary tumor site, compared to other primary tumor sites, local control was significantly better. OS outcomes were correlated with primary histology and primary tumor site; patients whose metastases had primary GI origin had superior OS. Factors associated with LC were tumor volume and physical and biologically effective dose coverage. Upon multivariable analysis, BED prescription dose was correlated with LC and GI as the primary site with OS. Most patients had no toxicity or grade 1 acute and late toxicity; one and two patients each experienced acute and late grade 3 radiation pneumonitis (RP), respectively. One patient who had a centrally located lesion and grade 4 RP died; the death was attributed to possible RT-induced pulmonary hemorrhage.The study appeared in <a href="https://bmccancer.biomedcentral.com/articles/10.1186/s12885-020-06906-1">BMC Cancer</a>.&ldquo;In conclusion, SBRT as delivered in this study is a highly effective local therapy for the treatment of de-novo metachronous-and repeat [ORLM] and might be able to sterilize a limited number of lesions and achieve long term survival rates in patients with more favourable prognostic features,&rdquo; summarized the authors.

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Robotic Stereotactic Body Radiotherapy Beneficial for Oligorecurrent Lung Metastases

Oncology

A recent study explored the effect of robotic stereotactic body radiotherapy (SBRT) in patients with oligorecurrent lung metastases (ORLM). ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe